Perrigo Company plc

NYSE:PRGO

Drug Manufacturers - Specialty & Generic

Healthcare
$16.94 -1.97%

-$0.20 today

Market cap
$2.35B
Beta
0.52
P/E (TTM)
-0.8
EPS (TTM)
-$13.10
Dividend yield
11.65%
52W Low $9.23High $28.44

Volume 2.57M

Average 2.96M

PRGO Long-term Debt

Borrowings due after more than one year.

Perrigo Company plcNYSE: PRGO

Long-term Debt · Q2 FY2026 · quarter ended Jun 2026

Long-term debt falls 8.9% from a year ago

Long-term debt stood at $3.28B at the end of Q2 FY2026, down 8.9% from a year earlier and down 9.1% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.

Context

  • Long-term debt amounted to 43.1% of total assets at the end of Q2 FY2026, up 7.4 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -8.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.28B-9.1% QoQ
Last fiscal yearDec 2025
$3.74B+4.5% YoY
Year agoJun 2025
$3.6B-8.9% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.9%——
1 year+4.5%——
3-year CAGR-2.8%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
3.74B USD
Year-over-year change
+4.5%
4-year CAGR
+6.4%

Long-term Debt vs competitors

How PRGO compares with its peers on the latest reported figures

  • PRGO's Jun 2026 long-term debt of $3.28B is the 2nd highest of the 10 companies compared; the peer median is $196.21M.
  • Its year-over-year change of -8.9% is the 6th highest of 8, against a peer median of -4.7%.
  • Long-term debt amounts to 43.1% of total assets for PRGO, versus a peer median of 10.9%.
PRGO Competitors Peer median
Long-term Debt for PRGO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BHCBausch Health Companies Inc.Jun 2026$19.88B -4.7%+0.6%80.2%
PRGOPerrigo Company plcJun 2026$3.28B -8.9%-2.8%43.1%
SGRYSurgery Partners, Inc.Sep 2026$3B +15.8%+1.9%42.5%
ATECAlphatec Holdings, Inc.Mar 2026$507.89M -7.0%+14.5%63.5%
LIVNLivaNova PLCSep 2026$295.2M -15.4%-8.8%10.9%
SRRKScholar Rock Holding CorporationSep 2026$196.21M +97.0%+26.1%44.0%
HCMHUTCHMED (China) LimitedDec 2025$68.19M +14.7%+55.6%3.9%
HTFLHeartflow, Inc. Common StockSep 2026$0 ——0.0%
TARSTarsus Pharmaceuticals, Inc.Sep 2026$0 -100.0%+62.3%0.0%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
Peer median (excluding PRGO) $196.21M-4.7%+14.5%10.9%

Competitors are the stored peer set for PRGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.86B600.7M751.3M558.8M531.6M
Short-term Investments00000
Net Receivables652.9M697.1M739.6M642.3M612.8M
Inventory1.02B1.15B1.14B1.08B1.15B
Other Current Assets16.1M271.8M201.1M199M504M
Total Current Assets3.86B2.72B2.83B2.48B2.8B
Property, Plant & Equipment (Net)1.03B1.14B1.1B1.09B1.07B
Goodwill3B3.49B3.53B3.32B2.05B
Intangible Assets2.15B3.29B2.99B2.43B2.35B
Long-term Investments000025.4M
Tax Assets6.5M7.1M25.8M5.1M3.3M
Other Non-current Assets377.5M367.7M335.2M318.6M236.4M
Total Non-current Assets6.57B8.3B7.98B7.17B5.74B
Total Assets10.43B11.02B10.81B9.65B8.54B
Account Payables411.2M537.3M477.7M495.2M474.5M
Short-term Debt603.8M36.2M440.6M36.4M62.3M
Tax Payables16.5M14.4M42.1M17.4M20.8M
Deferred Revenue00000
Other Current Liabilities49.1M(28.4M)00343.1M
Total Current Liabilities1.59B1.11B1.59B1.04B1.01B
Long-term Debt2.92B4.07B3.63B3.58B3.74B
Deferred Tax Liabilities239.3M368.2M262.3M203.2M168.9M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities382.8M433.5M559.8M499.2M511.3M
Total Non-current Liabilities3.69B5.06B4.45B4.28B4.59B
Total Liabilities5.27B6.18B6.04B5.33B5.6B
Common Stock7.04B6.94B6.84B6.73B6.61B
Retained Earnings(1.93B)(2.07B)(2.08B)(2.25B)(3.68B)
Accumulated OCI35.5M(27M)10.7M(162.4M)14.1M
Other Stockholders Equity0000(9.3M)
Minority Interest00000
Total Equity5.15B4.84B4.77B4.32B2.94B
Total Debt3.69B4.32B4.07B3.62B3.97B
Net Debt1.83B3.72B3.32B3.06B3.44B

Perrigo Company plc

NYSE:PRGO

Intrinsic Alpha fair value

Locked

Current Price

$16.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.